Enterprise Value
704.5K
Cash
7.41M
Avg Qtr Burn
-5.309M
Short % of Float
6.77%
Insider Ownership
0.94%
Institutional Own.
10.10%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DSUVIA (sufentanil) Details Post operative acute pain | Approved Quarterly sales | |
Nafamostat (Niyad™) Details Medical device | Phase 3 Initiation | |
Zalviso US (sufentanil) Details Post operative acute pain | Failed Discontinued |